GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » Equity-to-Asset

Marvel Biosciences (TSXV:MRVL) Equity-to-Asset : -7.95 (As of Apr. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Marvel Biosciences's Total Stockholders Equity for the quarter that ended in Apr. 2024 was C$-2.76 Mil. Marvel Biosciences's Total Assets for the quarter that ended in Apr. 2024 was C$0.35 Mil.

The historical rank and industry rank for Marvel Biosciences's Equity-to-Asset or its related term are showing as below:

TSXV:MRVL' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.95   Med: 0.21   Max: 0.96
Current: -7.95

During the past 4 years, the highest Equity to Asset Ratio of Marvel Biosciences was 0.96. The lowest was -7.95. And the median was 0.21.

TSXV:MRVL's Equity-to-Asset is ranked worse than
97.17% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs TSXV:MRVL: -7.95

Marvel Biosciences Equity-to-Asset Historical Data

The historical data trend for Marvel Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Equity-to-Asset Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23
Equity-to-Asset
0.40 0.96 0.21 -2.56

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.43 -2.56 -5.12 -3.45 -7.95

Competitive Comparison of Marvel Biosciences's Equity-to-Asset

For the Biotechnology subindustry, Marvel Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Equity-to-Asset falls into.



Marvel Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Marvel Biosciences's Equity to Asset Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Equity to Asset (A: Jul. 2023 )=Total Stockholders Equity/Total Assets
=-1.72/0.672
=

Marvel Biosciences's Equity to Asset Ratio for the quarter that ended in Apr. 2024 is calculated as

Equity to Asset (Q: Apr. 2024 )=Total Stockholders Equity/Total Assets
=-2.757/0.347
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marvel Biosciences  (TSXV:MRVL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Marvel Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Marvel Biosciences (TSXV:MRVL) Business Description

Traded in Other Exchanges
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
Executives
Joseph Roderick Matheson Director, Senior Officer